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showing that rat plasma does not give rise to peaks that interfere with the peaks originating from human IGF1 (used for preparation of the calibration curves) and 15 N-labeled human IGF1 (used as internal standard), or relevant IGF1 variants. analysis. With respect to the selected runs, the MALDI source was cleaned after run 8, thus run 1, 4 and 8 are shown to illustrate the effect of accumulating matrix deposits in the source, and run 12 is shown to illustrate the effect of cleaning the source. In order to calculate the relative abundances, the peak intensity of the oxidized analyte was divided by the sum of the peak intensities from the native and the oxidized analyte. To calculate the ratio, the relative abundance of the IGF1 oxidation peak was divided by the relative abundance of the 15 N-IGF1 oxidation peak.
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Figure S-4. Scatter plot of IGF1 levels based on the sum of non-oxidized and oxidized IGF1 plotted against IGF1 levels calculated using solely non-oxidized IGF1 for 4 (of the 13) analytical runs carried out for clinical sample analysis. With respect to the selected runs, the MALDI source was cleaned after run 8, thus run 1, 4 and 8 are shown to illustrate the effect of accumulating matrix deposits in the source, and run 12 is shown to illustrate the effect of cleaning the source.
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Figure S-5. Bland-Altman plots displaying the relative differences between IGF1 levels calculated using solely non-oxidized IGF1 and levels based on the sum of non-oxidized and oxidized IGF1 plotted against the average of both IGF1 levels for 4 (of the 13) analytical runs carried out for clinical sample analysis. With respect to the selected runs, the MALDI source was cleaned after run 8, thus run 1, 4 and 8 are shown to illustrate the effect of accumulating matrix deposits in the source, and run 12 is shown to illustrate the effect of cleaning the source.
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Figure S-6. Scatter plot of observed 4-spot coefficients of variation plotted against the relative IGF1 quantities for 4 (of the 13) analytical runs carried out for clinical sample analysis. With respect to the selected runs, the MALDI source was cleaned after run 8, thus the runs 1, 4 and 8 are shown to illustrate the effect of accumulating matrix deposits in the source, and run 12 is shown to illustrate the effect of cleaning the source.
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Figure S-7. Scatter plots for the comparison of IGF1 levels that are calculated using 1, 2 or 3 spots per sample versus IGF1 levels that are calculated using 4 spots per sample, as observed for 4 (of the 13) analytical runs carried out for clinical sample analysis. With respect to the selected runs, the MALDI source was cleaned after run 8, thus the runs 1, 4 and 8 are shown to illustrate the effect of accumulating matrix deposits in the source, and run 12 is shown to illustrate the effect of cleaning the source. Linear regression data belonging to the data series in the graphs above are presented in Table S-11. Furthermore, Table S -12 provides an overview of the relative differences between IGF1 levels that are calculated based on 4-spot IGF1/ 15 N-IGF1-ratios and levels that are calculated based on fewer spots per sample. Table S -12. Relative differences between IGF1 levels calculated using 1, 2 or 3 spots per sample and IGF1 levels that are calculated using 4 spots per sample. The table shows the number of samples per run (=81 samples) clustered based on the magnitude of the differences between the calculated levels.
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